These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 6220262

  • 21. In vitro activity of ertapenem: review of recent studies.
    Wexler HM.
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [Abstract] [Full Text] [Related]

  • 22. Comparative in vitro antibacterial activity of seven semi-synthetic penicillins against aerobic gram-negative bacteria and enterococci.
    Thabaut A, Durosoir JL, Saliou P.
    Infection; 1982 Jun; 10 Suppl 3():S249-56. PubMed ID: 7152690
    [Abstract] [Full Text] [Related]

  • 23. Ceftizoxime: a beta-lactamase-stable, broad-spectrum cephalosporin. Pharmacokinetics, adverse effects and clinical use.
    Neu HC.
    Pharmacotherapy; 1984 Jun; 4(2):47-60. PubMed ID: 6326062
    [Abstract] [Full Text] [Related]

  • 24. Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime.
    Gentry LO.
    Pharmacotherapy; 1985 Jun; 5(5):254-67. PubMed ID: 3906585
    [Abstract] [Full Text] [Related]

  • 25. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S, Hanaki H, Nagayama A.
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [Abstract] [Full Text] [Related]

  • 26. Comparative study of piperacillin versus cefoxitin in the treatment of obstetric and gynecologic infections.
    Sweet RL, Robbie MO, Ohm-Smith M, Hadley WK.
    Am J Obstet Gynecol; 1983 Feb 01; 145(3):342-9. PubMed ID: 6218755
    [Abstract] [Full Text] [Related]

  • 27. Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics. Part 2: penicillins.
    Barza M.
    Am J Hosp Pharm; 1977 Jan 01; 34(1):57-67. PubMed ID: 318800
    [Abstract] [Full Text] [Related]

  • 28. Piperacillin or ticarcillin plus amikacin. A double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients.
    Wade JC, Schimpff SC, Newman KA, Fortner CL, Standiford HC, Wiernik PH.
    Am J Med; 1981 Dec 01; 71(6):983-90. PubMed ID: 6459027
    [Abstract] [Full Text] [Related]

  • 29. Antibiotic use in neonatal sepsis.
    Yurdakök M.
    Turk J Pediatr; 1998 Dec 01; 40(1):17-33. PubMed ID: 9722468
    [Abstract] [Full Text] [Related]

  • 30. BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.
    Slocombe B, Basker MJ, Bentley PH, Clayton JP, Cole M, Comber KR, Dixon RA, Edmondson RA, Jackson D, Merrikin DJ, Sutherland R.
    Antimicrob Agents Chemother; 1981 Jul 01; 20(1):38-46. PubMed ID: 6974539
    [Abstract] [Full Text] [Related]

  • 31. Pharmacokinetics of intravenously administered piperacillin in preadolescent children.
    Thirumoorthi MC, Asmar BI, Buckley JA, Bollinger RO, Kauffman RE, Dajani AS.
    J Pediatr; 1983 Jun 01; 102(6):941-6. PubMed ID: 6222169
    [Abstract] [Full Text] [Related]

  • 32. Clinical use of beta-lactamase inhibitors in combination with extended-spectrum penicillins.
    Jones RN.
    Am J Health Syst Pharm; 1995 Mar 15; 52(6 Suppl 2):S29-33. PubMed ID: 7606587
    [Abstract] [Full Text] [Related]

  • 33. Timentin versus piperacillin in the therapy of serious urinary tract infections.
    File TM, Tan JS, Salstrom SJ, Johnson L.
    Am J Med; 1985 Nov 29; 79(5B):91-5. PubMed ID: 4073102
    [Abstract] [Full Text] [Related]

  • 34. Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.
    Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS.
    Drugs; 1983 Mar 29; 25(3):223-89. PubMed ID: 6303743
    [Abstract] [Full Text] [Related]

  • 35. Statistical comparison of the antibacterial activities of broad-spectrum penicillins against gram-negative bacilli.
    Fass RJ.
    Antimicrob Agents Chemother; 1983 Aug 29; 24(2):156-62. PubMed ID: 6638985
    [Abstract] [Full Text] [Related]

  • 36. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
    Young M, Plosker GL.
    Pharmacoeconomics; 2001 Aug 29; 19(11):1135-75. PubMed ID: 11735679
    [Abstract] [Full Text] [Related]

  • 37. The penicillins.
    Wright AJ, Wilkowske CJ.
    Mayo Clin Proc; 1983 Jan 29; 58(1):21-32. PubMed ID: 6218348
    [Abstract] [Full Text] [Related]

  • 38. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
    Borbone S, Cascone C, Santagati M, Mezzatesta ML, Stefani S.
    Int J Antimicrob Agents; 2006 Nov 29; 28(5):396-401. PubMed ID: 17045463
    [Abstract] [Full Text] [Related]

  • 39. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H, Hayakawa I, Akimoto T.
    Yakushigaku Zasshi; 2003 Nov 29; 38(2):161-79. PubMed ID: 15143768
    [Abstract] [Full Text] [Related]

  • 40. Piperacillin (T-1220), a new semisynthetic penicillin: in vitro antimicrobial activity comparison with carbenicillin, ticarcillin, ampicillin, cephalothin, cefamandole and cefoxitin.
    Jones RN, Thornsberry C, Barry AL, Fuchs PC, Gavan TL, Gerlach EH.
    J Antibiot (Tokyo); 1977 Dec 29; 30(12):1107-14. PubMed ID: 599084
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.